Benitec Biopharma Inc.

Informe acción NasdaqCM:BNTC

Capitalización de mercado: US$243.5m

Benitec Biopharma Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jerel Banks

Chief Executive Officer (CEO)

US$2.8m

Compensación total

Porcentaje del salario del CEO22.4%
Permanencia del CEO6.4yrs
Participación del CEOn/a
Permanencia media de la dirección6.4yrs
Promedio de permanencia en la Junta Directiva9.1yrs

Actualizaciones recientes de la dirección

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Recent updates

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma prices of $18M securities offering

Sep 13

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Sep 02

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12
Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27
Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02
How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jerel Banks en comparación con los beneficios de Benitec Biopharma?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$21m

Jun 30 2024US$3mUS$628k

-US$22m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023n/an/a

-US$22m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023US$919kUS$540k

-US$20m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022n/an/a

-US$19m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022US$800kUS$506k

-US$18m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021n/an/a

-US$18m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021US$1mUS$440k

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020n/an/a

-US$11m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020US$632kUS$400k

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019n/an/a

-US$6m

Sep 30 2019n/an/a

-US$2m

Jun 30 2019US$615kUS$400k

US$3m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

US$2m

Sep 30 2018n/an/a

-US$3m

Jun 30 2018US$91kn/a

-US$9m

Compensación vs. Mercado: La compensación total de Jerel($USD2.80M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.46M).

Compensación vs. Ingresos: La compensación de Jerel ha aumentado mientras la empresa no es rentable.


CEO

Jerel Banks (49 yo)

6.4yrs

Permanencia

US$2,798,977

Compensación

Dr. Jerel A. Banks, Ph D., M.D., has been the Chief Executive Officer of Benitec Biopharma Inc. since June 26, 2018. Dr. Banks has been the Executive Chairman of the Board at Benitec Biopharma Inc. since O...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Jerel Banks
Executive Chairman & CEO6.4yrsUS$2.80msin datos
Megan Boston
Executive Director6.4yrsUS$1.28m0.11%
$ 272.0k
Michael Graham
Head of Discovery & Founding Scientist9.4yrsUS$222.18ksin datos
Claudia Kloth
Senior Vice President of Manufacturingno datasin datossin datos

6.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de BNTC es experimentado (6.4 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Jerel Banks
Executive Chairman & CEO8.1yrsUS$2.80msin datos
Megan Boston
Executive Director8.3yrsUS$1.28m0.11%
$ 272.0k
J. Buchi
Independent Non-Executive Director11.6yrsUS$159.97k0.22%
$ 546.5k
Peter Francis
Independent Non-Executive Director18.8yrsUS$154.51k0.000080%
$ 194.8
Edward Smith
Independent Non-Executive Director4.6yrsUS$152.47k0%
$ 0
Kishan Mehta
Directorless than a yearsin datossin datos
Geoffrey McCaughan
Member of Hepatology Clinical Advisory Board9.1yrssin datossin datos
Harry Janssen
Member of Hepatology Clinical Advisory Board9.1yrssin datossin datos
Keyur Patel
Member of Hepatology Clinical Advisory Board9.1yrssin datossin datos
George Dickson
Member of Scientific & Clinical Advisory Boardno datasin datossin datos

9.1yrs

Permanencia media

52.5yo

Promedio de edad

Junta con experiencia: La junta directiva de BNTC se considera experimentada (9.1 años de antigüedad promedio).